Survival benefit in women with <i>BRCA1</i> mutation or familial risk in the <scp>MRI</scp> screening study (<scp>MRISC</scp>)
Sepideh Saadatmand(Erasmus MC), Madeleine M.A. Tilanus‐Linthorst(Erasmus University Rotterdam), Elisabeth Bergers(Alkermes (Ireland)), G.H. Woldringh(Radboud University Nijmegen), Emiel J. Rutgers(Oncode Institute), Rob A.�E.�M. Tollenaar(Leiden University Medical Center), Inge‐Marie Obdeijn(Erasmus MC), Maartje J. Hooning(Erasmus MC Cancer Institute), Harry J. de Koning(Erasmus MC), Jan C. Oosterwijk(University Medical Center Groningen), Eveline A.M. Heijnsdijk(Erasmus MC), Cornelis Verhoef(Erasmus MC Cancer Institute)
Cited by 97
Related Papers
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Efficacy of MRI and Mammography for Breast-Cancer Screening in Women with a Familial or Genetic Predisposition
|New England Journal of Medicine|2004|1.7k